Johnson & Johnson announced on April 22, 2026 that its new ETHICON 4000 Stapler has received European CE Mark approval, clearing the device for commercial sale throughout the European Union. The stapler incorporates proprietary 3‑D stapling technology that is designed to improve surgical precision and reduce operative time.
The approval expands J&J’s MedTech portfolio and provides a new revenue stream in a key international market. By addressing thick, fragile, or inconsistent tissue, the device improves staple line integrity and reduces the risk of leaks and bleeding—complications that can drive up costs and affect patient outcomes.
François Gaudemet, President of Surgery EMEA, MedTech, said that surgical complications can impact outcomes and have significant cost implications, and that the company is building on its legacy of supporting surgeons and driving innovation for consistent and reliable surgical experiences.
The ETHICON 4000 Stapler competes in a market that includes established players such as Medtronic. Its 3‑D stapling technology is positioned as a differentiator that offers improved staple line integrity compared with conventional staplers.
The device is intended for future integration with J&J’s OTTAVA™ Robotic Surgical System, which is still under development. The combination of advanced stapling technology with robotic precision is part of the company’s strategy to enhance minimally invasive surgical solutions.
J&J’s focus on MedTech has been reinforced by significant sales growth in the segment during Q1 2026 compared with Q1 2025, and by strategic acquisitions that broaden its product portfolio. The CE Mark approval is a milestone that supports the company’s broader MedTech growth strategy and its goal of expanding high‑margin surgical solutions in the EU.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.